Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 475
- Registration Number
- NCT03319667
- Locations
- 🇺🇸
Investigational Site Number: 8400006, Fort Myers, Florida, United States
🇺🇸Investigational Site Number: 8400004, Saint Petersburg, Florida, United States
🇺🇸Investigational Site Number: 8400007, Kansas City, Missouri, United States
A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)
- Conditions
- Rhinitis Allergic
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 260
- Registration Number
- NCT03317015
Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of Diabetes
- Conditions
- Type 1 Diabetes
- Interventions
- Drug: Blood draw for insulin auto-anti body tests*
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 375
- Registration Number
- NCT03312478
- Locations
- 🇵🇰
National Institute of Child Health, Karachi, Sind, Pakistan
Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects
- Conditions
- Type 1 Diabetes MellitusType 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 12
- Registration Number
- NCT03310944
- Locations
- 🇩🇪
Investigational Site Number 276001, Neuss, Germany
Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2017-09-15
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 136
- Registration Number
- NCT03284957
- Locations
- 🇨🇦
Investigational Site Number : 1240003, Vancouver, British Columbia, Canada
🇨🇦Investigational Site Number : 1240002, Toronto, Ontario, Canada
🇨🇿Investigational Site Number : 2030002, Brno, Czechia
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2017-09-07
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 302
- Registration Number
- NCT03275285
- Locations
- 🇺🇸
UCSF MS Center Site Number : 8400002, San Francisco, California, United States
🇺🇸Spartanburg Medical Center Site Number : 8400003, Spartanburg, South Carolina, United States
🇦🇺Investigational Site Number : 0360005, Blacktown, New South Wales, Australia
Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Drug: Insulin glargine, 300 units per milliliter (U/mL)
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 15
- Registration Number
- NCT03260868
- Locations
- 🇨🇦
Investigational Site Number 1240001, Barrie, Canada
🇨🇦Investigational Site Number 1240003, Oakville, Canada
🇺🇸Investigational Site Number 8400004, Houston, Texas, United States
A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
- Conditions
- Microvascular Coronary Artery Disease
- Interventions
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 10
- Registration Number
- NCT03236311
- Locations
- 🇺🇸
Investigational Site Number 8400001, Jacksonville, Florida, United States
🇺🇸Investigational Site Number 8400013, Wellington, Florida, United States
🇩🇰Investigational Site Number 2080001, København Nv, Denmark
Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine
- Conditions
- Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 597
- Registration Number
- NCT03211858
- Locations
- 🇺🇸
Investigational Site Number 8400033, Chattanooga, Tennessee, United States
🇺🇸Investigational Site Number 8400009, Dallas, Texas, United States
🇺🇸Investigational Site Number 8400024, Henderson, Nevada, United States
Sotagliflozin Bioequivalence Study
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 76
- Registration Number
- NCT03211195
- Locations
- 🇺🇸
Investigational Site Number 840001, Miami, Florida, United States